Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Swiss Medical Weeklyarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Swiss Medical Weekly
Article . 2014 . Peer-reviewed
License: CC BY NC SA
Data sources: Crossref
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Swiss Medical Weekly
Article
License: CC BY NC SA
Data sources: UnpayWall
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Swiss Medical Weekly
Article . 2015
Data sources: Europe PubMed Central
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Swiss Medical Weekly
Article . 2014
Data sources: DOAJ
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao
Archive ouverte UNIGE
Article . 2014
Data sources: Archive ouverte UNIGE
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao
Archive ouverte UNIGE
Article . 2014
Data sources: Archive ouverte UNIGE
https://dx.doi.org/10.4414/smw...
Article
Data sources: Microsoft Academic Graph
 View all 5 versions
Claim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

Update on multiple sclerosis treatments

descriptionPublicationkeyboard_double_arrow_right Article 21 Sep 2014Publisher:SMW Supporting AssociationJournal:Swiss Medical Weekly, volume 144, page w14012 (eissn: 1424-3997, Copyright policy )
Authors: Bridel, Claire; Lalive d'Epinay, Patrice;

doi: 10.4414/smw.2014.14012

pmid: 25247669

Update on multiple sclerosis treatments

Abstract

Relapsing-remitting multiple sclerosis (RRMS) management has dramatically changed over the past decade. New drugs have arrived on the market, allowing for more individualised treatment selection. However, this diversity has increased the complexity of RRMS patient follow-up. In this review, we provide summarised information about treatment efficacy, potential side-effects, follow-up recommendations, vaccinations, and pregnancy safety issues for all currently available disease modifying therapies and those awaiting approval.

Related Organizations
Keywords

616.8, Daclizumab, Toluidines, Dimethyl Fumarate, Hydroxybutyrates, Interferon-beta/therapeutic use, Immunoglobulin G/therapeutic use, Antibodies, Monoclonal, Humanized, Multiple sclerosis, Multiple Sclerosis, Relapsing-Remitting, Fumarates, disease modifying therapies, Sphingosine, Crotonates/therapeutic use, Nitriles, Humans, fingolimod, interferon beta, Propylene Glycols/therapeutic use, Alemtuzumab, Fingolimod Hydrochloride, Fumarates/therapeutic use, Natalizumab, R, Interferon-beta, Multiple Sclerosis, Relapsing-Remitting/drug therapy, Antibodies, Monoclonal, Humanized/therapeutic use, Toluidines/therapeutic use, Propylene Glycols, Crotonates, Immunoglobulin G, recommendations, glatiramer acetate, Immunosuppressive Agents/administration & dosage/adverse effects/therapeutic use, Medicine, Sphingosine/analogs & derivatives/therapeutic use, Immunosuppressive Agents, ddc: ddc:616.8

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 8
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    		 Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    		 Top 10%
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
8
Average
Average
Top 10%
Published in a Diamond OA journal
Related to Research communities
Knowmad Institut
Neuroscience